Can you provide a table of long‑acting muscarinic antagonists (LAMA), long‑acting β2‑agonists (LABA), and short‑acting β2‑agonists (SABA) with their uses and preparations according to the latest GINA (Global Initiative for Asthma) guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

LAMA, LABA, and SABA Medications in Asthma Management

Based on current asthma guidelines, here is a comprehensive table of bronchodilator medications with their specific uses and preparations:

Medication Table by Drug Class

Long-Acting Muscarinic Antagonists (LAMA)

Drug Preparation/Device Use in Asthma Dosing
Tiotropium Respimat inhaler Add-on to ICS-LABA in uncontrolled moderate-severe asthma (ages ≥12 years) Separate inhaler device
Glycopyrronium Single inhaler (triple therapy) Combined with ICS-LABA as single-inhaler triple therapy Part of ICS/LABA/LAMA combination
Umeclidinium Single inhaler (triple therapy) Combined with ICS-LABA as single-inhaler triple therapy Part of ICS/LABA/LAMA combination

Long-Acting β2-Agonists (LABA)

Drug Preparation/Device Use in Asthma Dosing
Formoterol Combined with ICS (various inhalers) Maintenance therapy combined with ICS; Can be used as maintenance AND reliever therapy (MART) 1-2 puffs as needed in MART regimen
Salmeterol Combined with ICS (various inhalers) Maintenance therapy combined with ICS only Twice daily maintenance only
Vilanterol Combined with ICS Maintenance therapy combined with ICS Once daily maintenance

Short-Acting β2-Agonists (SABA)

Drug Preparation/Device Use in Asthma Dosing
Albuterol/Salbutamol MDI, nebulizer solution Quick-relief for acute symptoms As needed; up to 3 treatments at 20-min intervals; Max 8-12 puffs/day depending on age
Levalbuterol MDI, nebulizer solution Quick-relief for acute symptoms As needed for symptom relief

Clinical Application by Treatment Step 1

Ages 12+ Years:

  • Step 1: PRN SABA only
  • Step 2: Daily low-dose ICS + PRN SABA
  • Step 3: Daily medium-dose ICS + PRN SABA (or low-dose ICS-LABA)
  • Step 4: Daily medium-dose ICS-LABA + PRN SABA; Alternative: Add LAMA to medium-dose ICS
  • Step 5: Daily high-dose ICS-LABA + PRN SABA; Consider adding LAMA
  • Step 6: Daily high-dose ICS-LABA + LAMA + oral corticosteroid

Ages 5-11 Years:

  • Step 1: PRN SABA only
  • Step 2: Daily low-dose ICS + PRN SABA
  • Step 3: Daily medium-dose ICS + PRN SABA
  • Step 4: Daily high-dose ICS-LABA + PRN SABA
  • Step 5-6: High-dose ICS-LABA ± oral corticosteroid

Note: LAMA is not prominently featured in pediatric guidelines for ages 5-11 in the provided evidence 1

Key Clinical Points About LAMA Use

LAMA should be added to ICS-LABA therapy in patients with persistent uncontrolled asthma despite medium-to-high dose ICS-LABA 2, 3, 4. This triple therapy approach:

  • Reduces exacerbations
  • Improves lung function (FEV1)
  • Enhances asthma control
  • Improves quality of life

Predictive Factors for LAMA Efficacy 2, 5:

Better response seen in:

  • History of ≥1 exacerbation in past 12 months
  • Male patients
  • Age <65 years
  • Non-smokers
  • High bronchial hyperresponsiveness
  • Persistent airway limitation
  • Lower baseline FEV1

Important: Eosinophil levels do NOT predict LAMA efficacy 2

Triple Therapy Options 6, 7:

  1. Closed triple therapy: Single inhaler containing ICS/LABA/LAMA (glycopyrronium or umeclidinium combinations)

    • Advantage: Better adherence with single device

  2. Open triple therapy: Separate LAMA inhaler (tiotropium) added to ICS-LABA combination

    • Advantage: Flexibility in dosing adjustments

Critical Safety Considerations

SABA Overuse Warning 1:

SABA use >2 days/week for symptom relief (excluding exercise-induced bronchoconstriction prevention) indicates inadequate control and requires stepping up maintenance therapy. This is a red flag for poor asthma control and increased exacerbation risk.

Maximum SABA Dosing:

  • Ages 12+: Up to 12 puffs (54 mcg) total daily
  • Ages 5-11: Up to 8 puffs (36 mcg) total daily

MART Regimen (Maintenance and Reliever Therapy):

In Steps 3-4, ICS-formoterol can be used as both maintenance (daily) and rescue therapy (1-2 puffs as needed) 1. This approach is preferred over conventional SABA-only rescue therapy in appropriate patients.

Common Pitfalls to Avoid

  1. Do not use LAMA as monotherapy - Always combine with ICS ± LABA
  2. Do not use LABA without ICS - Increases mortality risk
  3. Do not delay LAMA addition - Consider before escalating to biologics or systemic corticosteroids 7, 4
  4. Single-inhaler triple therapy improves adherence over multiple devices 4
  5. LAMA works across all asthma phenotypes - No need for specific phenotyping before initiation 3, 5

References

3
Research

Understanding the role of long-acting muscarinic antagonists in asthma treatment.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022

4
Research

Optimizing asthma management: Role of long-acting muscarinic antagonists.

The Journal of allergy and clinical immunology, 2022

7
Research

The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma.

Journal of aerosol medicine and pulmonary drug delivery, 2023

Related Questions

Where do leukotriene receptor antagonists (LTRAs), long‑acting muscarinic antagonists (LAMAs), long‑acting β₂‑agonists (LABAs), and inhaled corticosteroids (ICS) fit into the treatment algorithm for adult asthma?
What are the contraindications for using long‑acting muscarinic antagonists (LAMA) in patients with ocular hypertension?
What are the long‑acting muscarinic antagonists (LAMA), inhaled corticosteroids (ICS), and short‑acting β2‑agonists (SABA) and their typical dosing regimens?
What alternative asthma treatment without corticosteroids can be used for a patient on Trelegy with increased intraocular pressure?
How do you choose between adding a long-acting muscarinic antagonist (LAMA) or a leukotriene receptor antagonist (LTRA) in asthma step-up therapy when fractional exhaled nitric oxide (FeNO) and eosinophils are normal?
What is the appropriate management for a patient with ascites and severe hyperkalemia (potassium 6.0 mEq/L)?
Does the presence of suicidal ideation automatically exclude an adjustment disorder and require a diagnosis of major depressive disorder?
Does Super Beets contain vitamin K?
Is a liquid formulation of Zoloft (sertraline) at 20 mg per ml equivalent to a 20‑mg tablet dose?
Can exposure to the Southwest Asia/Gulf War cause obstructive sleep apnea (OSA)?
What is the appropriate dosing and usage instructions for docusate sodium 200 mg taken twice daily for constipation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.